Optimising therapy in newly diagnosed metastatic Ewing sarcoma
Optimising tyrosine kinase inhibitor therapy in newly diagnosed metastatic Ewing sarcoma
Developing personalised treatments for brain-directed chemotherapy in childhood acute lymphoblastic leukaemia
ALLTogether1 CSF-FLOW Study
Advance testing efficacy of albendazole in childhood acute myeloid leukaemia
Investigating the preclinical efficacy of albendazole in paediatric acute myeloid leukaemia
Factors which affect survival following relapse in neuroblastomas
Clinical and biological factors associated with relapse and length of survival following relapse in UK neuroblastomas
Phase II clinical trial: Testing a new therapy to treat children with relapsed/ refractory cancers and immune system over-activation conditions
GOTHAM - A phase II trial to assess the activity of Gemtuzumab Ozogamicin Therapy in HAemophagocytic lymphohistiocytosis (HLH)/Macrophage activation syndrome (MAS) or relapsed/refractory cancers
Developing a ‘biodegradable paste’ to deliver chemotherapy directly to the brain to treat childhood brain tumours
Neurosurgically-applied chemotherapy for childhood brain tumours arising in the posterior fossa using a biodegradable paste
The Little Princess Trust Knowledge Bank of Wilms Tumour
The Little Princess Trust Knowledge Bank of Wilms Tumour
Reducing pain caused as a side effect of vincristine chemotherapy
Can we reduce or eliminate the sensory nerve damage caused by vincristine chemotherapy? Potential novel adjunct neuroprotective/analgesic therapies.
Stopping ‘cut-and-run’ DNA errors to help treat leukaemia and predict relapse
Towards inhibiting cut-and-run: An aberrant V(D)J recombination reaction that leads to lymphoid cancers